Now I have all the information needed for a calibrated review. Let me finalize.

**Calibration summary across all rounds:**

| Anchor | Path | Avg Score | Round | Itemized? | Comparison |
|--------|------|-----------|-------|-----------|------------|
| TB prediction | V83xzYnZ5q | 3.00 | R1 | Yes | Less novel method, weaker contribution; our paper is stronger |
| Physiome-ODE | 6ouZaBzeNO | 3.75 | R1 | Yes | Benchmark paper with stronger contribution but different scope |
| PDEDER (dynamics) | i1BTP8wFYM | 5.25 | R1 | Yes | Stronger evaluation, similar generalization idea |
| PEMs (epidemic pre-train) | DL7JWbdGr3 | 4.75 | R1+R2 | Yes | **Most comparable anchor** — same problem, stronger evaluation, rejected |
| Contrastive Meta Dynamics | S8nFZ98pmU | 4.75 | R2 | Yes | Related dynamics generalization, rejected |
| SNODEP (metabolic) | FmoInsWCkp | 3.50 | R2 | Yes | Less novel methodology, evaluation concerns |
| Financial forecasting | 53gU1BASrd | 4.50 | R2 | No | Different domain |
| CloudOps pre-training | ZkEsEFFUyo | 4.33 | R2 | No | Different domain |

**Round-1 bracket:** 3.0 – 5.0 (anchored by TB prediction at 3.00 and PEMs at 4.75)

**Final placement within bracket:** The closest anchor is PEMs (4.75), which tackled the same cross-disease pre-training problem with substantially stronger evaluation (more baselines, held-out COVID-19 test). Our paper has a more interesting architecture (deep+compartmental) but significantly weaker evaluation (2-location external comparison, unexplained ablation anomaly). This places the paper below PEMs. Among lower anchors, SNODEP (3.50) had weaker methodological novelty, while TB prediction (3.00) had weaker everything. Our paper's mix of strong methodological design but weak evaluation places it between these — at approximately **4.0**.

**Favorability comparison with PEMs (4.75):** PEMs' strongest items were "strong experimental results" (favorability=15.07) and "reasonable experimental design" (13.52). Our strongest items are "method design coherent" (10.12) and "problem importance" (9.37). Our weakest items are "DELPHI implausibly poor" (-2.18) and "external comparison too thin" (-1.67). PEMs' weakest items include "limited baselines" (-3.55) and "missing simpler baselines" (-0.28). The comparison confirms our paper has stronger methodological novelty but weaker evidential support, justifying a score below 4.75.

---

## Summary

The paper proposes HG-DCM, a two-stage framework that uses a ResNet (without BatchNorm) to predict parameters of the DELPHI compartmental model, trained jointly on historical pandemic data (Ebola, SARS, Dengue, seasonal Flu) and limited early-stage COVID-19 data. The goal is to improve "cold-start" pandemic forecasting when current-outbreak data is very scarce (2–8 weeks). The paper also contributes a multi-pandemic dataset.

## Strengths

- **Well-motivated and timely problem.** Early-stage pandemic forecasting when data is scarce is a real open challenge, and the idea that macro-level outbreak dynamics share regularities across biologically distinct diseases (because they are shaped by human behavior and public-health responses) is intuitively plausible. The paper articulates this clearly (Section 1).

- **Method design is coherent and domain-aware.** The two-stage pipeline (deep learning → compartmental model) is sound. Removing BatchNorm from the ResNet because batch statistics differ across pandemics (Section 2.1) is a thoughtful architectural choice reflecting genuine domain understanding. Using DELPHI as the downstream compartmental model adds realism over simpler SIR/SEIR.

- **Dataset construction is a concrete service.** Assembling a multi-pandemic dataset (COVID-19, Ebola, SARS, Dengue, seasonal Influenza) with metadata is non-trivial and would be a useful resource for the community if released.

## Weaknesses

### Major

- **External comparison (Table 1) is far too thin to support the paper's strong claims.** The comparison against GradABM and EiNNs is conducted on only **two locations** (Massachusetts and the United States), selected solely due to data/code availability. Moreover, even on this minimal set, HG-DCM does not consistently win: EiNNs beats HG-DCM on the US 4-week task (MAE 729,091 vs. 2,548,004) and on the Massachusetts 6-week task (25,669 vs. 39,887). The paper claims HG-DCM "consistently and significantly outperforms state-of-the-art methods" (lines 33, 212) and establishes "a new paradigm" (line 9), but the evidence from only two locations with mixed results does not support these assertions.

- **The ablation study (Table 2) contains unexplained failures that directly contradict the paper's narrative.** At the 2-week training window, HG-DCM's mean MAE (18,603) is *worse* than both CNN (15,600) and T-DCM (15,049). At the 4-week window, HG-DCM's mean MAE (110,452) is an **order of magnitude worse** than CNN (11,238) and ~6× worse than T-DCM (17,691). The paper states "CNN generally underperforms HG-DCM across all training horizons" (line 188), which the *mean* MAE results contradict. These failures are not discussed anywhere in the paper, and this is a serious omission for a method claiming to improve forecasting stability.

- **The extreme mean–median gap at 4 weeks signals catastrophic failures on a subset of locations.** HG-DCM's mean MAE at 4 weeks is 110,452 while its median is 1,770 — a ~62× gap. This indicates that on some locations, predictions are wildly inaccurate. The paper claims HG-DCM provides "more stable" predictions (line 170) and reduces overshooting (Figure 4a), but does not characterize or explain these failure cases. For a method intended as a public-health decision-support tool, understanding where and why it fails is essential.

### Minor

- **DELPHI baseline performance raises implementation questions.** DELPHI's reported MAEs (342,686 at 2 weeks, 813,807 at 4 weeks) are orders of magnitude worse than even a simple CNN (15,600 and 11,238), despite DELPHI being a top COVID-19 Forecast Hub performer. While poor performance on very short training windows is consistent with the paper's motivation, the magnitude is so extreme that it suggests implementation or configuration issues the paper does not address. The DELPHI-vs.-HG-DCM comparison is thus less informative than it could be.

- **No confidence intervals or significance tests for forecasting comparisons.** Tables 1 and 2 report only point estimates. With only two locations in Table 1 and a heavily skewed distribution in Table 2, error bars or per-location breakdowns are needed.

- **Hyperparameter β (past vs. current loss balance, Eqn. 5) is not analyzed.** This parameter controls the core knowledge-transfer mechanism, and its sensitivity is relevant given the much larger number of past-pandemic samples compared to current-pandemic samples.

- **No per-disease ablation.** It is unclear whether all historical pandemics contribute equally or whether the benefit is driven primarily by seasonal Influenza (most similar to COVID-19). This would clarify the mechanism.

- **Framing partially oversells the "novel pathogen" scenario.** The experimental setup (line 128) trains on 2–8 weeks of COVID-19 data alongside historical pandemics — this is a data-augmentation / cold-start setup, not a true held-out cross-disease transfer test. The paper's language ("systematically transferring knowledge from historical pandemics to the current outbreak," "novel pathogen") somewhat overstates what is actually evaluated.

### Trivial

None.

## Nice-to-Haves

- A held-out disease experiment (train on all diseases except COVID-19, test on COVID-19 with no COVID-19 data in training) would directly validate the cross-disease transfer claim.
- Population-normalized metrics (per 100,000) would make results more interpretable across locations of vastly different population sizes.
- An analysis of the 4-week mean MAE spike — which locations drive it, and why — would substantially strengthen the paper.

## Removed Points

These points are flagged to be removed; treat them with caution:

- **Division by zero in MAPE loss** — Removed because the paper excludes locations with cumulative cases below 100 and sets start dates at the first day cumulative cases exceed 100 (lines 88, 124), so C_ij > 0 in all training data. Not a real problem.
- **Window-shift augmentation corrupting temporal structure** — Removed as a speculative concern without concrete evidence of harm.
- "**Comprehensive dataset**" **overstatement** — Removed as a minor phrasing issue, not a substantive weakness.
- **Formatting/style nitpicks** — Removed as parser artifacts, not author errors.

## Novel Insights

None beyond the paper's own contributions. The reviews surface a tension between the paper's ambitious claims ("new paradigm," "novel pathogen" transfer) and the limitations of its evaluation (2-location external comparison, unexplained ablation anomaly at 4 weeks) that the paper itself does not acknowledge. This is a standard gap-finding observation rather than a novel insight about the method itself.

## Suggestions

1. Report the 4-week mean MAE anomaly explicitly, investigate its causes (specific subset of locations? training instability?), and discuss implications.
2. Add a held-out disease experiment (train on all diseases except COVID-19, test on COVID-19) to directly validate cross-disease transfer.
3. Include confidence intervals or per-location error distributions for all reported MAE values.
4. Ablate the β hyperparameter and report sensitivity.
5. Provide per-disease ablation to show which historical pandemics contribute most to the improvement.

MY FINAL SCORE: <score>4.0</score>
MY FINAL DECISION: <decision>Reject</decision>